Immunoprofiling assays
Evaluate the status of the immune system

Immunoprofiling for drug development

Cell and gene therapies require monitoring of immune system activation. Bioanalysis, such as biodistribution, shedding, and pharmacokinetics, cannot be trusted if the immune response degrades the drug. In clinical trials, the therapeutic effect can be lost, or activation of the immune system can result in serious adverse effects. We have the tools to monitor the immune response.

Early and adaptive immune activation

Precise immune response measurements

The immune system protects us from foreign microorganisms, but in the case of cell and gene therapies, it’s crucial for the introduced foreign nucleic acids to have minimal impact on the immune response. We measure both the immediate innate immune response and the adaptive immune response using qPCR, dPCR, NGS, and Olink’s protein profiling.

Immunoprofiling TATAA
Innate immune response TATAA

Effortless cytokine monitoring

Using Olink’s Target 48 Cytokine panels, the nonspecific, rapid innate immune response can be easily monitored. These panels, designed for use with mouse or human samples, provide absolute quantification of key cytokines using only microliters of blood or plasma, allowing for precise measurement and comparison between samples. We perform the analysis with minimal hands-on time, with all pipetting done by robots.

Blood sample for adaptive immune system

TCR and BCR repertoire sequencing

With optimized, high-throughput sequencing of T-cell receptors and B-cell receptors, we monitor the adaptive immune system. This allows us to evaluate how a drug affects the immune system and to track treatment efficacy through the persistence and expansion of engineered T-cells in CAR-T treatments.

The Olink Target 96 panels are designed for high throughput, cost efficiency, and low sample consumption, facilitating targeted biomarker research in various disease areas and biological processes. Explore Our Olink Services The Olink Target 96 panels simultaneously enable high-multiplex targeting

Immunosequencing entails the high-throughput sequencing of T-cell (TCR) and B-cell receptors (BCR), offering invaluable insights into the immune response within CAR-T therapies. Download the blog as PDF. T-cell malignancies following CAR-T therapy There is a potential risk of secondary cancers


Let's explore how we can support your drug development program.

PK/PD​ bioanalysis

General Biodistribution Page

"*" indicates required fields